Bruker Corporation (BRKR)
Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab
Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.
Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.
Rags to Riches: 3 Nanotech Stocks That Could Make Early Investors Rich
Business leaders often talk about thinking big. But when it comes to nanotech stocks, the future is all about focusing on the small things.
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
Peeling Back The Layers: Exploring Bruker Through Analyst Insights
Throughout the last three months, 4 analysts have evaluated Bruker BRKR, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. In the assessment of 12-month price targets, analysts unveil insights for Bruker, presenting an average target of $85.75, a high estimate of $102.00, and a low estimate of $74.00. This upward trend is apparent, with the current average reflecting a 2.08% increase from the previous average price target of $84.00. A clear picture of Bruker's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Bruker's future value. Examining the current and prior targets provides insight into analysts' changing expectations. Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bruker's market position. Stay informed and make well-informed decisions with our Ratings Table. Stay up to date on Bruker analyst ratings. Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific. Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity. Revenue Growth: Bruker's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 7.05%. This signifies efficient cost management and strong financial health. Return on Equity (ROE): Bruker's ROE stands out, surpassing industry averages. With an impressive ROE of 3.65%, the company demonstrates effective use of equity capital and strong financial performance. Return on Assets (ROA): Bruker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.16%, the company showcases efficient use of assets and strong financial health. Debt Management: With a high debt-to-equity ratio of 1.03, Bruker faces challenges in effectively managing its debt levels, indicating potential financial strain. Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter. Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors. If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro. This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Bruker (NASDAQ:BRKR) Releases FY 2027 Earnings Guidance
Bruker (NASDAQ:BRKR – Get Free Report) issued an update on its FY 2027 earnings guidance on Friday morning. The company provided EPS guidance of 4.000-4.300 for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion. Bruker Stock Performance Bruker stock opened at $75.07 on Monday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. The firm’s fifty day moving average price is $84.74 and its 200 day moving average price is $76.45. The company has a market capitalization of $10.91 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 1.79 and a beta of 1.22. Bruker has a 12-month low of $53.79 and a 12-month high of $94.86. Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 earnings per share. On average, research analysts forecast that Bruker will post 2.81 EPS for the current fiscal year. Bruker Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 17th. Investors of record on Monday, June 3rd will be given a dividend of $0.05 per share. The ex-dividend date is Friday, May 31st. This represents a $0.20 dividend on an annualized basis and a yield of 0.27%. Bruker’s dividend payout ratio is currently 7.27%. Wall Street Analysts Forecast Growth Several research firms have recently issued reports on BRKR. The Goldman Sachs Group increased their price target on Bruker from $66.00 to $74.00 and gave the stock a sell rating in a research note on Wednesday, April 10th. Stifel Nicolaus boosted their price target on shares of Bruker from $63.00 to $81.00 and gave the stock a hold rating in a research report on Wednesday, February 14th. JPMorgan Chase & Co. upgraded shares of Bruker from a neutral rating to an overweight rating and increased their price objective for the company from $60.00 to $90.00 in a report on Wednesday, February 14th. UBS Group upped their target price on Bruker from $94.00 to $102.00 and gave the stock a buy rating in a research report on Friday, March 1st. Finally, Citigroup lifted their price target on Bruker from $80.00 to $95.00 and gave the company a buy rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $84.86. Get Our Latest Stock Report on Bruker Insider Buying and Selling In other news, Director Hermann Fritz Requardt sold 15,000 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $90.06, for a total value of $1,350,900.00. Following the sale, the director now owns 23,147 shares in the company, valued at $2,084,618.82. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 28.30% of the company’s stock. About Bruker (Get Free Report) Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. See Also Five stocks we like better than Bruker 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion JD’s Earnings Could Mean Chinese Stocks Making a Comeback How to Invest in Biotech Stocks Canada Goose Flies Higher Driven By DTC Growth Health Care Stocks Explained: Why You Might Want to Invest CVS Health Stock Has a Silver Lining Called Value
